Centratherum anthelminticum seeds administration improved risk factor markers in metformin treated type 2 diabetic patients.

This study was designed to assess the effect of Centratherum anthelminticum seeds administration on blood and serum risk factor markers in type 2 diabetic (T2D) patients using metformin. It was a randomized non-blinded, controlled, 3month trial. T2D patients were registered from Sindh Government Hospital New Karachi, Karachi. There were 3 groups, DT (Diabetic Test, n=20), DC (Diabetic Control, n=20) HC (Healthy Control n=20, healthy individuals of similar age were selected). DC (metformin 500mg), DT (capsule of C. anthelminticum seeds powder CAPca + metformin 500mg each) and HC (CAPca 500mg) were given daily. Fasting blood glucose, body weights were monitored weekly while blood samples were collected on first and final day of the trial for biochemistry. Administration of CAPca showed significant decrease in % glycaemia (p<0.0001) and % Hb glycosylation (p<0.05) values. Serum risk factor markers including direct bilirubin & uric acid (p<0.01), creatine kinase & alanine aminotransferase (p<0.0001) and creatinine (p<0.05) were reduced significantly. CAPca administration improved blood and serum markers in healthy volunteers too. These improved blood & serum markers in T2D patients indorsed synergistic effect of CAPca with metformin to manage secondary challenges of T2D.

Persea americana seeds improve glycosylation and dyslipidemia in fructose-fed streptozotocin-injected type 2 diabetic male rats.

This work explored the in-vitro phytochemical contents and antidiabetic activity of crude seeds powder of Persea americana (CSSPa) and their in-vivo biochemical effects on glycated hemoglobin, lipid profile and other parameters in type 2 diabetic rats (fructose-STZ model). There were 2 groups of over night fasted rats, control (normal diet) and diabetic (35% Fructose for 6 weeks followed with injection (i.p.) of streptozotocin (STZ) (40mg/kg bw). Diabetic group was further divided into diabetic control, positive control (pioglitazone 15mg) and test (CSSPa 500mg) groups. After the appropriate treatments in each group for 2 weeks fasting glucose level (FGL), serum lipids, insulin, alanine aminotransferase (ALT), creatine Kinase (CK) & uric acid were determined. CSPPa showed presence of alkaloids, flavonoids, phenols etc and potent antidiabetic activity with IC50 13.23±0.76µM. CSPPa treatment showed a significant (p<0.01) decline in lipid profile, while HDL showed significant increase (p<0.01) in test group as compared with positive and diabetic control groups. The serum ALT, CK, uric acid, bilirubin & fasting glucose (fbg) showed significant improvements in test group (p<0.01). Coronary risk index (CRI), Fasting insulin resistance index (FIRI), Percent glycemic change (PGC) and HbA1c values also significantly (p<0.01) improved.